Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mint Med vs Vytora Health

Mint Med
Graded #22

Higher grade

vs+12.400000000000006
Vytora Health
Graded #79

Lower grade

The verdict

Mint Med takes it — 84.7/100 to 72.3/100.

Mint Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Low both-molecule pricing ($117/$159) and verified — but only 36 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMint Med +31
90
59
Dose & formulationVytora Health +5
80
85
Clinical oversightVytora Health +11
85
96
Labs & monitoringMint Med +28
83
55
FulfillmentVytora Health +14
82
96
Contract termsMint Med +66
86
20
Mint Med · left barVytora Health · right bar

The numbers

MetricMint MedVytora Health
WeighScore84.7/10072.3/100
GradeBC
Scorecard rank#22#79
Semaglutide$117/mo$180/mo (all doses, compounded)
Tirzepatide$159/mo$249/mo (all doses, compounded)
Coverage36 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Mint Med

Graded #22 · B

Strengths

  • $117 sema / $159 tirz
  • LegitScript-verified
  • Both molecules

Where it loses points

  • Only 36 states
  • Injection-only
  • Monitoring detail sparse
Vytora Health

Graded #79 · C

Strengths

  • All 50 states plus DC, with per-state video-vs-audio compliance disclosed
  • Both compounded and brand-name options on one platform — uncommon
  • LegitScript Approved and HIPAA compliant
  • Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
  • Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)

Where it loses points

  • Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
  • Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
  • Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
  • Initial consultation cost not shown on the public pricing page
  • Limited per-prescriber state licensure detail

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard